Simcere Pharmaceutical Group Overview
- Year Founded
-
1995
- Status
-
Public
- Employees
-
7,661
- Stock Symbol
-
02096
- Investments
-
13
- Share Price
-
$0.87
- (As of Friday Closing)
Simcere Pharmaceutical Group General Information
Description
Simcere Pharmaceutical Group Ltd is engaged in the R&D, production and commercialization of pharmaceuticals focused on generic pharmaceuticals. It has a diversified product portfolio focused on therapeutic areas, including, oncology (including cell therapy), nervous system diseases, autoimmune diseases and antiinfection. The company's products include Endostar, Enweida, Iremod, Sanbexin and Others.
Contact Information
- 699-18, Xuanwu Avenue
- Nanjing, Jiangsu 210042
- China
Simcere Pharmaceutical Group Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.87 | $0.88 | $0.74 - $1.88 | $2.3B | 2.62B | 4.99M | $0.17 |
Simcere Pharmaceutical Group Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 |
|---|---|---|---|---|
| EV | 2,477,937 | 3,769,344 | 3,003,103 | 3,476,577 |
| Revenue | 1,006,293 | 938,311 | 774,300 | 652,623 |
| EBITDA | 450,656 | 170,112 | 256,488 | 164,273 |
| Net Income | 451,995 | 138,505 | 233,402 | 96,913 |
| Total Assets | 1,749,377 | 1,562,639 | 1,594,130 | 1,675,020 |
| Total Debt | 159,420 | 218,391 | 256,645 | 505,107 |
Simcere Pharmaceutical Group Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Simcere Pharmaceutical Group Comparisons
Industry
Financing
Details
000000
Simcere Pharmaceutical Group Competitors (1)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| 000000 | Private Equity-Backed | Pune, India | 0000 | 00.000 | 00000000 | 00.000 |
Simcere Pharmaceutical Group Patents
Simcere Pharmaceutical Group Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4176868-A4 | Stable pharmaceutical composition | Pending | 17-Aug-2020 | 000000000 | 0 |
| EP-4176868-A1 | Stable pharmaceutical composition | Pending | 17-Aug-2020 | 000000000 | |
| AU-2021329765-A1 | Stable pharmaceutical composition | Pending | 17-Aug-2020 | 000000000 | |
| CA-3188671-A1 | Stable pharmaceutical composition | Pending | 17-Aug-2020 | 000000000 | |
| JP-2023539573-A | Stable pharmaceutical composition | Pending | 17-Aug-2020 | A61K47/02 |
Simcere Pharmaceutical Group Executive Team (11)
Simcere Pharmaceutical Group Board Members (3)
| Name | Representing | Role | Since |
|---|---|---|---|
| 00000000 000 | Simcere Pharmaceutical Group | Chief Executive Officer & Chairman | 000 0000 |
| 000000 000 | Simcere Pharmaceutical Group | Chief Financial Officer, Finance & Board Member | 000 0000 |
Simcere Pharmaceutical Group Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Simcere Pharmaceutical Group Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Simcere Pharmaceutical Group Investments (13)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Neurondawn Pharmaceutical | 06-Feb-2023 | 00000 0000 | 000.00 | Drug Discovery | |
| Carmine Therapeutics | 29-Nov-2022 | 00000 0000 | 000.00 | Biotechnology | |
| Neurondawn Pharmaceutical | 23-Jul-2022 | 00000 0000 | Drug Discovery | ||
| Reju Therapeutics | 14-Oct-2021 | 000000000 | Drug Discovery | ||
| Neurondawn Pharmaceutical | 23-Aug-2021 | Early Stage VC | 000.00 | Drug Discovery |
Simcere Pharmaceutical Group Subsidiaries (2)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| Simcere | Diagnostic Equipment | Nanjing, China | 2017 |
| Jilin Boda pharmaceutical | Pharmaceuticals | Liaoyuan, China | 0000 |
Simcere Pharmaceutical Group ESG
Risk Overview
Risk Rating
Updated February, 04, 2023
31.33 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.00
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 15,708
Rank
Percentile
Pharmaceuticals
Industry
00 of 884
Rank
Percentile
Pharmaceuticals
Subindustry
00 of 418
Rank
Percentile
Simcere Pharmaceutical Group Exits (3)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| 3D Medicines | 23-Dec-2019 | 00000 00000 00 | 00000 | Completed |
|
| I-Mab Biopharma | 30-Jun-2016 | 0000 00000 | 00.00 | Completed |
|
| Shanghai Celgen Biopharma | 01-Aug-2009 | Corporate | Completed |